Alnylam Pharmaceuticals, Inc. has grown revenue 53% a year over three years and 50% a year over five. Revenue growth, 3-year annual rate: +53% (Biotechnology median +17%). Revenue growth, 5-year rate: +50%, growth has picked up over the last three years. Years of annual history on file: 18, FY2008 to FY2025, as filed.

ALNYAlnylam Pharmaceuticals, Inc.

Healthcare

$232.57-49% 1Y

$232.57

$216.4652 weeks$491.22

Is it growing?

Mixed

Neither accelerating nor breaking down: revenue growing +65% year on year and operating margin widening (+19.2 points), but earnings down −191% year on year.

2 good, 1 to watch

Revenue trend+65% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +50% a year.

Earnings trend−191% in a year

Trailing-twelve-month earnings per share against a year earlier. Growing slower than revenue, so the growth is costing something.

Margin direction+19.2 points operating

Trailing-twelve-month operating margin, 10.6% now against -8.6% a year earlier.

All from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Revenue growth, 3 yearstop 1% of the market

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is ALNY growing?

Alnylam Pharmaceuticals, Inc. has grown revenue 53% a year over three years and 50% a year over five.

+53%

Revenue growth, 3-year annual rate · Biotechnology median +17% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +50%
Revenue growth, 5-year rate · +53% over three · growth has picked up over the last three years
Years of annual history on file: 18
Years of annual history on file · FY2008 to FY2025, as filed

Details›